FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 9, 2016

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On February 9, 2016, Second Sight Medical Products, Inc. (the “Company” or “Second Sight”) issued a press release announcing that it had entered into a distribution agreement with Tecnosalud, S.A., a corporation based in Argentina. Under the agreement Tecnosalud will distribute the Argus® II Retinal Prosthesis System ("Argus II") in Argentina and will be in charge of executing in-country management of all aspects of Second Sight’s technology, including programming, importation, supply and surgical support of the Company’s products in Argentina.

A copy of our press release entitled “Second Sight Announces Exclusive Agreement with Tecnosalud to Bring the Argus II Retinal Prosthesis to Argentina” issued February 9, 2016 is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2016

SECOND SIGHT MEDICAL PRODUCTS, INC.